Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease

BACKGROUND: To date, there's no evidence of an increased risk of SARS-CoV-2 infection or more severe COVID-19 in patients with inflammatory bowel disease (IBD). However, whether COVID-19 alters the clinical course of IBD or whether IBD treatment affects the immunological response to SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosa, Luca, Di Chiara, Costanza, Gaio, Paola, Cosma, Chiara, Padoan, Andrea, Cozzani, Sandra, Perilongo, Giorgio, Plebani, Mario, Giaquinto, Carlo, Donà, Daniele, Cananzi, Mara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866952/
https://www.ncbi.nlm.nih.gov/pubmed/35223697
http://dx.doi.org/10.3389/fped.2022.815857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866952/
https://www.ncbi.nlm.nih.gov/pubmed/35223697
http://dx.doi.org/10.3389/fped.2022.815857

Ejemplares similares